71 results about "Receptor Tyrosine Kinase Inhibitors" patented technology

The invention discloses a receptor tyrosine kinases inhibiting type targeting medicament curative effect related gene mRNA expressive level detection Luminex. The detection Luminex mainly comprises a micro-ball, supporting extending probes, and amplification extension probes. The micro-ball is coupled with a supporting probe modified by amino; the supporting extending probes are used for connecting the supporting probe and a target gene mRNA, and each supporting extending probe comprises a specific sequence the terminal 5' of which can combine with a corresponding target gene mRNA, a spacer arm sequence, and a sequence the terminal 3' of which can complementarily pair with the corresponding specific sequence of the supporting probe at; and the amplification extension probes are used for connecting the target gene mRNA and information detection components, and each amplification extension probe comprises a specific sequence the terminal 5' of which can combine with the corresponding target gene mRNA, a spacer arm sequence, and a sequence the terminal 3' of which can complementarily pair with a markup probe. The invention also discloses a detection method of the receptor tyrosine kinases inhibiting type targeting medicament curative effect related gene mRNA expressive level by using the liminex. In the invention, the process can be carried out without the steps of RNA extraction, reverse transcription, PCR and the like and the detection result is influenced less by the quality of RNA in the sample, thereby the accuracy of the detection result is guaranteed; on the other hand, because the liminex technology enables a parallel multi-index detection to be realized, multiple inside genes can be set in one detection, thereby the detection result is more reliable.

Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK / PI3 kinase / AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and / or vi) an effective amount of trastuzumab or TMD1, and / or combinations thereof; and an effective amount of a bispecific anti-ErbB2 / anti-ErbB3 antibody. Also disclosed is a bispecific anti-ErbB2 / anti-ErbB3 antibody for use in the therapy of a tumor in combination with an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK / PI3 kinase / AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and / or vi) an effective amount of trastuzumab or TMD1, and / or combinations thereof.

The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and / or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.

The invention discloses a class of compounds capable of being used as an insulin-like growth factor-1 receptor tyrosine kinase inhibitor, and a preparation method thereof, a pharmaceutical compositioncontaining the compound, and applications of the pharmaceutical composition in prevention or treatment of tumors, especially brain glioma.

The invention belongs to the field of antiviral medicines, and discloses application of a receptor tyrosine kinase inhibitor in preparation of a medicine for preventing and / or treating novel coronavirus infection. The receptor tyrosine kinase inhibitor comprises mosatinib, alectinib, roxatidine or pharmaceutically acceptable salts of the small molecular compounds. The receptor tyrosine kinase inhibitor such as mosatinib, alectinib and roxatidine can strongly inhibit synthesis of replicon RNA of a novel coronavirus SARS-CoV-2 and reduce the RNA copy amount of a wild type novel coronavirus SARS-CoV-2 in cells, so that replication of the novel coronavirus SARS-CoV-2 is inhibited, and the receptor tyrosine kinase inhibitor has the effect of preventing and / or treating novel coronavirus SARS-CoV-2 infection.